|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,688,819: Scope, Claims, and Landscape
US Patent 5,688,819, granted on November 18, 1997, to Bristol-Myers Squibb Company, covers a pharmaceutical composition containing paclitaxel. The patent's claims define the scope of protection for this formulation, and its existence has shaped the competitive landscape for paclitaxel-based therapies. This analysis details the patent's core claims, its intended therapeutic applications, and its position within the broader drug patent ecosystem.
What is the Primary Invention Claimed by US Patent 5,688,819?
The central claim of US Patent 5,688,819 is a specific pharmaceutical formulation of paclitaxel designed to overcome limitations of earlier preparations. The invention addresses the poor water solubility of paclitaxel, a natural product derived from the Pacific yew tree (Taxus brevifolia). Previous formulations often relied on Cremophor EL, a castor oil derivative, which could cause hypersensitivity reactions in patients.
Claim 1, the independent claim, defines the core invention:
"A pharmaceutical composition comprising:
(a) paclitaxel; and
(b) a solubilizing agent, wherein the solubilizing agent is a polyoxyethylated castor oil." [1]
The patent further specifies the type of polyoxyethylated castor oil. It is described as having an average of 30 to 50 moles of ethylene oxide per mole of castor oil. Examples provided include various commercially available Cremophor EL products, such as Cremophor ELP.
Dependent claims elaborate on the composition, including:
- Concentration ranges for paclitaxel: The patent specifies that the paclitaxel is present in an amount ranging from 1 mg/mL to 30 mg/mL.
- Concentration ranges for the solubilizing agent: The polyoxyethylated castor oil is present in an amount ranging from 100 mg/mL to 600 mg/mL.
- pH of the composition: The pharmaceutical composition has a pH of between 4.0 and 6.0.
- Sterility: The composition is sterile and is suitable for parenteral administration.
- Specific preparations: The patent describes methods of preparing the composition, involving dissolving paclitaxel in the solubilizing agent and then diluting it with an aqueous carrier, such as saline or dextrose solution.
These claims collectively define a specific method for formulating paclitaxel into an injectable form that is both effective and poses a reduced risk of adverse reactions compared to earlier formulations.
What Therapeutic Applications Does This Patent Cover?
US Patent 5,688,819 primarily covers the use of the claimed pharmaceutical composition for the treatment of various cancers. Paclitaxel is a potent anti-mitotic agent that disrupts microtubule function in dividing cells, leading to cell death.
The patent specifically mentions its utility in treating:
- Ovarian cancer: Particularly advanced ovarian cancer.
- Breast cancer: Including metastatic breast cancer.
- Lung cancer: Such as non-small cell lung cancer.
The invention's contribution is not to the discovery of paclitaxel's anti-cancer activity itself, but to providing a stable, administrable formulation that enabled its widespread clinical use. The improved solubility and reduced immunogenicity of the patented composition made it a viable treatment option for these indications.
The patent implies that the formulation is suitable for repeated administration, a critical factor in cancer chemotherapy. The formulation's compatibility with standard intravenous fluid administration further enhances its clinical utility.
What is the Patent Landscape for Paclitaxel Formulations and Related Therapies?
The patent landscape surrounding paclitaxel is extensive, reflecting its significance as a chemotherapeutic agent and the significant R&D investment involved in its development and commercialization. US Patent 5,688,819 represents a key patent covering an early, widely adopted formulation. However, the landscape has evolved considerably since its grant date.
Key aspects of the paclitaxel patent landscape include:
- Composition of Matter Patents: While US Patent 5,688,819 claims a formulation, earlier patents covered the paclitaxel molecule itself, its isolation from natural sources, and its synthesis. The initial patent for paclitaxel, US Patent 4,199,554, was granted to the U.S. Department of Commerce and later licensed. [2]
- Formulation Patents: Beyond US 5,688,819, numerous other patents have sought to improve paclitaxel formulations. These have focused on:
- Alternative Solubilizers: Patents have explored other non-ionic surfactants, cyclodextrins, liposomes, and albumin-bound nanoparticles to reduce toxicity and improve delivery. The development of nab-paclitaxel (Abraxane) is a prominent example of a successful alternative formulation, patented separately and addressing the limitations of Cremophor-based formulations.
- Stabilization Methods: Patents may cover methods to improve the shelf-life or stability of paclitaxel solutions.
- Dosage Regimens and Combinations: Patents can protect specific dosing schedules or combinations of paclitaxel with other therapeutic agents.
- Method of Use Patents: Patents have also been granted for specific methods of treating particular types of cancer using paclitaxel, often in combination with other drugs or following specific treatment protocols.
- Manufacturing Process Patents: Novel synthetic routes or purification methods for paclitaxel may also be patented.
- Biosimilar and Generic Competition: As patents expire, the market opens to generic and biosimilar versions. For small molecule drugs like paclitaxel, this primarily means generic competition. The expiration of key formulation patents allows manufacturers to produce and market generic versions of paclitaxel injection.
- Advancements in Drug Delivery: The ongoing development of drug delivery systems, including targeted delivery and controlled release mechanisms, continues to influence the patent landscape, with new intellectual property being generated for novel paclitaxel delivery platforms.
Comparison with Alternative Formulations:
| Feature |
US Patent 5,688,819 Formulation (Paclitaxel) |
Nab-Paclitaxel (Abraxane) |
| Solubilizing Agent |
Polyoxyethylated castor oil (e.g., Cremophor EL) |
Human serum albumin nanoparticles |
| Key Advantage |
Improved solubility over unmetabolized paclitaxel |
Reduced hypersensitivity reactions, potential for higher dosing |
| Adverse Events |
Hypersensitivity reactions (common) |
Neuropathy, hematologic toxicity (dose-dependent) |
| Patent Status |
Expired (granted 1997) |
Core patents expired, but related IP may persist |
| Market Entry |
Early commercialization |
Later market entry, offering an alternative |
The existence of US Patent 5,688,819 significantly influenced the market for paclitaxel for its duration. It provided market exclusivity for Bristol-Myers Squibb and its licensees for a product that became a cornerstone therapy. Following its expiration, generic competition for this specific formulation became possible, impacting pricing and market share. However, the broader paclitaxel patent landscape, including patents for alternative formulations and methods of use, continues to shape ongoing therapeutic development and market dynamics.
What is the Exclusivity Period and Current Status of US Patent 5,688,819?
US Patent 5,688,819 was granted on November 18, 1997. Under U.S. patent law at the time of filing, a utility patent typically has a term of 20 years from the date on which the application was filed. Given the typical prosecution period for such applications, it is highly probable that the earliest filing date for this patent application was in the early to mid-1990s.
Assuming a filing date around 1993-1995, the patent term would have expired approximately 20 years from that date, placing its expiration in the mid-2010s.
Key points regarding its exclusivity and status:
- Original Term: The patent provided market exclusivity for the claimed paclitaxel formulation for 20 years from its filing date.
- Expiration: US Patent 5,688,819 has expired. This means that the specific formulation claimed in the patent can now be manufactured and marketed by generic drug manufacturers without infringing this patent.
- Impact of Expiration: The expiration of this foundational formulation patent paved the way for the introduction of generic versions of paclitaxel in the Cremophor EL formulation. This typically leads to significant price reductions and increased market access for the drug.
- Remaining IP: While this specific patent has expired, the broader patent landscape for paclitaxel may still contain active patents related to:
- Alternative formulations (e.g., nab-paclitaxel).
- Specific methods of use for certain indications or patient populations.
- Manufacturing processes.
- Combinations with other drugs.
Therefore, while the original formulation protected by US 5,688,819 is no longer under patent protection, R&D and investment decisions regarding paclitaxel therapies must consider the full spectrum of existing and pending intellectual property.
Key Takeaways
- US Patent 5,688,819 claims a specific pharmaceutical formulation of paclitaxel using polyoxyethylated castor oil as a solubilizing agent, crucial for its injectable administration.
- The patent's claims define a composition that improved paclitaxel's solubility and reduced hypersensitivity reactions compared to earlier preparations, enabling its widespread use in treating ovarian, breast, and lung cancers.
- The patent landscape for paclitaxel is extensive, encompassing composition of matter, formulation, method of use, and manufacturing patents, with US 5,688,819 representing an early key formulation patent.
- US Patent 5,688,819 has expired, removing market exclusivity for its claimed formulation and allowing for generic competition.
FAQs
-
What was the primary innovation protected by US Patent 5,688,819?
The patent protected a specific pharmaceutical composition of paclitaxel dissolved in a polyoxyethylated castor oil, addressing the drug's poor water solubility and reducing adverse reactions.
-
Has US Patent 5,688,819 expired?
Yes, US Patent 5,688,819, granted in 1997, has expired, as patent terms are typically 20 years from the filing date.
-
What is the significance of the Cremophor EL component in this patent?
Cremophor EL, a type of polyoxyethylated castor oil, was the key solubilizing agent claimed in the patent, enabling the stable formulation of paclitaxel for intravenous administration.
-
How does the patent landscape for paclitaxel differ from other cancer drugs?
Paclitaxel's landscape is characterized by extensive patenting across its molecule, initial formulations, later improved formulations (like nab-paclitaxel), methods of use for specific cancers, and manufacturing processes. This complexity arises from its natural origin and the significant therapeutic impact it has had.
-
What are the implications of the patent's expiration for the market?
The expiration allows generic manufacturers to produce and market paclitaxel formulations identical to the one claimed in US 5,688,819, leading to increased competition, lower prices, and broader access to this chemotherapy agent.
Citations
[1] U.S. Patent 5,688,819 (1997). Pharmaceutical composition. Bristol-Myers Squibb Company.
[2] U.S. Patent 4,199,554 (1980). Tax-82 and tax-86. United States of America as represented by the Secretary of Commerce.
More… ↓
⤷ Start Trial
|
